Federal Reports

To see our report, click on the link below

Technology is driving a heightened level of innovation in product and service offerings in the current last mile parcel delivery market and is transforming the way delivery providers interact with their customers. It has empowered customers with tools like real-time tracking, and has raised their expectations. Consumers now expect delivery to be flexible, visible, and fast — all at a low price. It is also democratizing the last mile, which is witnessing an invasion by a variety of new entrants able to enter the market without the need for considerable investment in labor or capital, from large ecommerce platforms, to brick and mortar retailers and even small startups.

Manufacturer rebates for drugs paid through Medicaid managed care organizations (MCOs) are an increasingly important source of savings for both States and the Federal government. However, "duplicate discounts," which occur when manufacturers pay Medicaid rebates on drugs sold at the already discounted 340B price, are prohibited by law. Thus, for States to collect allowable rebates only and avoid duplicate discounts for drugs paid through MCOs, they must identify and exclude 340B drug claims. If a State does not accurately identify 340B drug claims, both duplicate discounts and forgone rebates-that is, unclaimed rebates to which States are legally entitled-may occur. Duplicate discounts result in manufacturers paying too much in rebates, while forgone rebates result in States paying too much for drugs.